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Abstract
Tauopathies, the most common of which is Alzheimer’s disease (AD), constitute the most 
crippling neurodegenerative threat to our aging population. Tauopathic patients have significant 
cognitive decline accompanied by irreversible and severe brain atrophy, and it is thought that 
neuronal dysfunction begins years before diagnosis. Our current understanding of tauopathies has 
yielded promising therapeutic interventions but have all failed in clinical trials. This is partly due 
to the inability to identify and intervene in an effective therapeutic window early in the disease 
process. A major challenge that contributes to the definition of an early therapeutic window is 
limited technologies. To address these challenges, we modified and adapted a manganese-
enhanced magnetic resonance imaging (MEMRI) approach to provide sensitive and quantitative 
To whom correspondence should be addressed: Jose Abisambra, joe.abisambra@uky.edu, Sanders-Brown Center on Aging, University 
of Kentucky, 800S Limestone St, Lexington, KY 40536-0230. 
Declarations
All authors consent publication of this manuscript. There are no competing interests. Funding for this work came from the University 
of Kentucky Alzheimer’s Disease Center (UK-ADC), which is supported by NIH/NIA P30 AG028383. JFA, SNF, AI, RAC. SEM, 
EM, DL, GKN, and EM, were supported by NIH/NINDS 1R01 NS091329-01, Alzheimer’s Association NIRG-14-322441, NIH/
NCATS 5UL1TR000117-04, NIH/NIGMS 5P30GM110787, Department of Defense AZ140097, the University of Kentucky Epilepsy 
Center (EpiC), NIH/NIA P30 AG028383, and NIH/NIMHD L32 MD009205-01. We acknowledge Dr. Donna Wilcock for use of the 
AxioScan, Dr. Peter Davies for the MC1 antibody, and Dr. Frederick Schmitt for comments on this manuscript and insights into these 
experiments. Author contributions are as follows: JFA designed the study. SNF, AI, SEM, EM, and DL performed MRI. MV 
developed analysis program for MEMRI and MV, DL, SEM, and RAC analyzed MEMRI data. AI and EM performed mouse 
husbandry and with SNF, tissue collection. SNF performed all IHC and analysis. SNF, MV and JFA interpreted data and wrote the 
paper. Data and materials will be made widely available upon reasonable request to the corresponding author.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Neurobiol Aging. Author manuscript; available in PMC 2018 August 01.
Published in final edited form as:
Neurobiol Aging. 2017 August ; 56: 78–86. doi:10.1016/j.neurobiolaging.2017.04.007.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
power to detect changes in broad neuronal function in aging mice. Considering that tau tangle 
burden correlates well with cognitive impairment in Alzheimer’s patients, we performed our 
MEMRI approach in a time course of aging mice and an accelerated mouse model of tauopathy. 
We measured significant changes in broad neuronal function as a consequence of age and, in 
transgenic mice, before the deposition of bona fide tangles. This MEMRI approach represents the 
first diagnostic measure of neuronal dysfunction in mice. Successful translation of this technology 
in the clinic could serve as a sensitive diagnostic tool for the definition of effective therapeutic 
windows.
Keywords
MEMRI; tau; tangles; manganese; rTg4510; Alzheimer
1. Introduction
Alzheimer’s disease (AD) and related tauopathies are the most crippling cognitive threat to 
the aging population. There is no cure for tauopathies, and this is partly because of unclear 
understanding of tau pathogenesis. It is expected that in the United States we will spend 
approximately $1.2 trillion to maintain the constantly deteriorating quality of life of 16 
million Americans with AD by 2050 (Alzheimer’s, 2016). Despite promising results in in 
vivo models, therapeutic interventions fail to halt the disease process, and they only provide 
temporary benefits. A major challenge in the field is the lack of sensitive technologies to 
identify pre-symptomatic signs of disease. Consequently, neuronal damage in the patient 
population recruited for clinical trials might be too far advanced for therapeutics to be 
effective. Therefore, there is a critical need to identify an early therapeutic window in the 
prodromal stage of disease.
The current diagnostic imaging measure of pre-AD relies on amyloid plaque detection. 
Individuals are screened using anti-amyloid ligands (florbetapir) with positron emission 
tomography (PET) (Carome and Wolfe, 2011; Choi et al., 2009; Klunk et al., 2004; Mathis 
et al., 2004). In addition, development of effective and specific tau tangle ligands such 
as 18F-T807 accelerated the possibility of measuring both pathological signs of AD and 
discriminating several diseases (Chien et al., 2014; Johnson et al., 2016; Marquie et al., 
2015). There are several challenges for using PET technology to diagnose neurodegenerative 
processes. Accessibility to PET instruments is limited by location and cost, curtailing 
widespread availability of this technique. Moreover, the merging of PET molecular 
signatures to anatomical features requires the addition of structural imaging and in the case 
of computed tomography imaging, which leads to double exposure to radiation. The most 
pivotal obstacle with current imaging diagnostics is their focus on correlation between 
cognitive damage and mature pathology. Individuals in the prodromal stages of disease are 
only identified after PET-positive amyloid pathology appears. Moreover, [F18]-AV-1451 
tracers detect PHF1-positive aggregates, which correspond to late stage tangles enriched 
with pS396/S404 tau. Therefore, individuals who present pathological signs of disease and 
mild (mild cognitive impairment) to moderate symptomatology likely suffer simultaneous 
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irreversible neurodegenerative processes making therapeutic interventions less efficacious 
(Dubois et al., 2016).
In contrast, access to MRI technology is widely available, and does not require the use of 
ionizing radiation. MRI can be combined with contrast enhancement agents to increase the 
sensitivity of this technique. Manganese-enhanced MRI (MEMRI) offers a powerful tool to 
repeatedly measure neuronal function in longitudinal in vivo studies. MEMRI is particularly 
well suited for brain imaging because manganese enters voltage-gated ion channels 
proportionally to calcium flux (Lin and Koretsky, 1997) and shortens the T1 relaxation time 
of neighboring water (Antkowiak et al., 2012; Bissig and Berkowitz, 2014; Drapeau and 
Nachshen, 1984; Koretsky and Silva, 2004; Vandsburger et al., 2012). Once in a neuron, 
manganese is trafficked through the cells and released in the post-synaptic density (Pautler et 
al., 1998), and this activity-dependent uptake and trafficking correlates with broad neuronal 
function (Pautler and Koretsky, 2002). In addition, manganese is taken up preferentially in 
the hippocampus (Shineman et al., 2011), a key brain region involved in learning and 
memory. Therefore, MEMRI is a powerful technique to quantify broad neuronal function in 
brain regions affected by age and neurodegenerative disease.
We tested the value of combined MEMRI and mapping of T1 relaxation times coupled with 
T2-mapping to determine changes in signatures over time and with disease in the rTg4510 
transgenic mouse model of accelerated tauopathy (Santacruz et al., 2005). MEMRI 
recognized alterations in broad neuronal function during in pre-symptomatic stages of pre-
tangle pathology. Our results suggest that MEMRI is a sensitive, widely available, and non-
invasive in vivo imaging technique for identification of early stages of neurodegeneration.
2. Materials and Methods
2.1 Mice and Ethics Approval
All animal studies were approved by the University of Kentucky’s Institutional Animal Care 
and Use Committee (IACUC) and abided by that committee’s policies on animal care and 
use in accordance with the Guide for the Care and Use of Laboratory Animals, the Animal 
Welfare Regulations Title 9 Code of Federal Regulations Subchapter A, “Animal Welfare,” 
Parts 1–3, and the Public Health Service Policy on Humane Care and Use of Laboratory 
Animals. This University of Kentucky program and the facilities for animal care and use are 
fully accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International. The animals were kept in standard housing on a 14h light/10h dark cycle 
and received food and water ad libitum. The tau transgenic (rTg4510) and parental mice 
(rTta and TRE-4R0N-P301L MAPT, on a FVB background) were maintained and genotyped 
as described previously (Santacruz et al., 2005). All experiments were done in both male and 
female mice.
For MEMRI studies, at each age group (2, 3, and 10 months) a naïve group of mice were 
subjected to one MEMRI scan. As we observed no differences in MEMRI between 
TRE-4R0N P301L MAPT (tau), rTta and wt littermates, each experiment was performed 
with age and sex matched littermates of the non-rTg4510 genotype (ctrl).
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2.2 Manganese-enhanced magnetic resonance imaging (MEMRI)
All MRI procedures were performed in accordance with the University of Kentucky 
Magnetic Resonance Imaging and Spectroscopy Core (MRISC) IACUC Protocol. 
Manganese, which is identical in charge and similar in ionic radius to calcium, enters 
voltage-gated calcium channels on neuronal membranes, follows calcium trafficking, and is 
released in the synaptic cleft and internalized by the postsynaptic neuron (Masumiya et al., 
2003; Pautler et al., 1998). Manganese is also a potent MRI contrast agent that lengthens R1 
(1/T1) relaxation rates as a function of concentration in tissue (Vandsburger et al., 2012). 
When MEMRI is combined with an imaging protocol to quantify tissue R1 relaxation rates, 
the acquired data reflects an in vivo measurement of underlying function of cells with 
voltage gated calcium channels (Antkowiak et al., 2012). Manganese chloride (30mM) 
prepared in saline was delivered to mice via intraperitoneal injection (66mg/kg). All MR 
imaging was performed on a horizontal bore 7T Bruker ClinScan magnet (Bruker, Ettlingen, 
Germany) using a cylindrical volume coil for excitation and a cryocoil for detection. In 
preparation for imaging, animals are anesthetized using isoflurane (3–5%) in oxygen at a 
rate of 0.5–1.0 L/min and maintained using 1–3% isoflurane in oxygen. Body temperature 
was maintained using circulating water, and vital signs (core temperature and respirations) 
were monitored using a physiological monitoring system SA Instruments Inc. (SAI, Stony 
Brook, New York). Look-Locker imaging was performed following non-selective spin 
inversion in one slice of the brain containing large regions of hippocampus. Fifty images 
were acquired following inversion with image spacing of 100ms (total sequence repetition 
time of 5s) to fully sample the T1-relaxation curve. Additional image parameters included 
TR/TE = 5500/1.9, Matrix = 128 × 128, number of averages = 3, field of view = 17mm × 
17mm × 0.7mm. T2-weighted images were acquired covering the entire brain (excluding the 
cerebellum and olfactory bulb) using a turbo-spin echo sequence with TR/TE = 3360/42, 
Slices = 21, Matrix = 448 × 336, number of averages = 2, field of view = 25mm × 25mm × 
0.5mm. The imaging procedures for scanning one mouse were completed in 45min. Imaging 
was performed prior to the injection of MnCl2 (baseline) and repeated at 6h post-injection 
(Fig. 1). Image mapping and analysis was performed in MATLAB (Mathworks, Nattic, MA, 
USA). Images from the Look-Locker series were used to reconstruct voxel-by-voxel signal 
relaxation curves which were fit to the equation S(TI) = So*(1−e−R1*TI), where S(t) 
represents the signal at a given inversion time (TI), So represents the steady state signal at 
maximal TI, and R1 represents the longitudinal relaxation rate. Regions of interest (dentate 
gyrus, CA1, CA3, and superior medial cortex) were identified using the Allen Brain Mouse 
Atlas. Within each the change in R1 relaxation rates (ΔR1) before and after MnCl2 exposure 
was calculated as
2.3 Immunohistochemistry
Following MEMRI, mice were irreversibly anesthetized, exsanguinated, and transcardially 
perfused with saline followed by 4% phosphate-buffered paraformaldehyde (PFA, pH 7.4), a 
protocol mildly modified from (Abisambra et al., 2010b). Brain samples were fixed in 4% 
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paraformaldehyde for 24 hr, then cryoprotected by incubating in successive 24 h increments 
with 10%, 20%, and 30% sucrose gradients as described previously (Jinwal et al., 2010). 
Brains were frozen on a temperature-controlled freezing stage, sectioned (25 μm) on a 
sliding microtome, and stored in a solution of PBS containing 0.02% sodium azide at 4°C.
Free-floating immunohistochemistry was performed as described (Abisambra et al., 2010a). 
The following antibody dilutions were used: pS262 (Anaspec) 1;10,000; pT231 (Invitrogen) 
1:25,000; MC1 (kind gift from P. Davies) 1:2500. IHC sections were imaged using a Zeiss 
AxioScan (Zeiss, Germany). Image quantification was performed using ImageJ as follows: 
regions of interest (CA1, CA3, DG, and cortex) in 2–4 coronal sections per mouse were 
quantified. Then, all images were thresholded identically and intensity was measured for 
each region of interest. Quantifications shown are mean ± standard error of the mean.
2.4 Statistical analysis
All statistical analyses for MEMRI were performed using GraphPad Prism 6 (Graph Pad 
Software, Inc. La Jolla, CA, USA). Results are shown as the mean ± standard error. Data 
from figure 2 were analyzed using two-way ANOVA with a Bonferroni posttest. Data from 
figures 3 and 4 were analyzed using a student’s unpaired t-test. A p<0.05 was considered 
significant. For immunohistochemistry, any outliers two standard deviations from the mean 
were excluded. Two way ANOVAs with multiple comparison post-hoc tests were performed 
to identify statistically significant differences using GraphPad Prism 6 software. A 
confidence interval of 95% (p<0.05) was considered statistically significant.
3. Results
We first investigated MEMRI viability as a method to reveal age-related changes in wild 
type mice. Since aging impacts calcium homeostasis, overall learning and memory, and 
neuronal connectivity (Gray and Johnston, 1987; Landfield, 1988; Sastry et al., 1986), we 
speculated that MEMRI could detect age-dependent alterations in brain regions where these 
functions are crucial. We first established a baseline model in control mice by performing 
MEMRI scans at in groups of mice aged two, three, six, and ten months of age. 
Representative coronal sections of high-resolution R1 maps are shown for each age group 
(Figure 2A–D). Quantification of ΔR1 revealed increased changes in relaxation rates (ΔR1, 
where R1 = 1/T1) in hippocampal regions CA1, CA3, and DG (Figure 1A, Figure 2E–G) as 
well as in the superior medial cortex (Figure 2H). In all regions, there was an initial increase 
in ΔR1 values from two to three months, followed by a sharp decrease in ΔR1 values as 
animal age increases (Figure 2E–H), suggesting manganese uptake decreases with age. 
These results suggest MEMRI is a sensitive and quantitative technique to distinguish age-
related alterations in non-transgenic mice. We next sought to determine whether ΔR1 values 
could distinguish differences between age-related and neurodegenerative disease-associated 
alterations.
MEMRI successfully detected differences in AD mouse models overexpressing APP (Smith 
et al., 2007) and has been used to examine axonal transport rates in olfactory bulbs of 
rTg4510 (Majid et al., 2014). Because cognitive decline is closely associated with 
pathogenic tau accumulation, we used rTg4510 mice to identify whether MEMRI 
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specifically detects changes in regions of the brain negatively impacted by tauopathy. Tau 
transgenic rTg4510 mice express very high levels of human tau with a pathogenic mutation 
associated with FTDL17 (Santacruz et al., 2005). Pre-tangle pathology matures into bona 
fide Alzheimer’s-like tau tangles by four months of age (Ramsden et al., 2005; Santacruz et 
al., 2005). This pathological transition precedes moderate yet significant 
electrophysiological deficits and cognitive impairments, which become evident after 3.5 
months and 4 months, respectively (Abisambra et al., 2013; Abisambra et al., 2010b; 
Ramsden et al., 2005). By 5.5 months, rTg4510 mice show overt tangle pathology along 
with significant cognitive decline and brain atrophy (Santacruz et al., 2005). These signs and 
symptoms are further potentiated with age: at ten months, rTg4510 mice show larger tangles 
reminiscent of those present in fronto-temporal lobar degeneration brains, ~20% reduction in 
brain weight, and more severe cognitive deficits than 5.5-month-old transgenic mice 
(Ramsden et al., 2005).
We hypothesized that alterations in broad neuronal function caused by severe tau pathology 
would be detectable by MEMRI. We performed MEMRI ΔR1 analyses in 10mo rTg4510 
transgenic mice, an advanced stage in the disease showing significant brain atrophy, tau 
pathology, and cognitive impairment. Indeed, MEMRI ΔR1 revealed gross abnormalities in 
rTg4510 brain morphology: cortical thinning (Figure 3B) and accumulation of cerebrospinal 
fluid (blue color, Figure 3B). Comparison of pre- and post-contrast R1 maps revealed that 
rTg4510 mice have significantly increased ΔR1 (Figure 3B–C) in CA1, and dentate gyrus 
regions of the hippocampus, as well as in the cortex compared to age-matched littermate 
control mice (Figure 3A–C). There was no difference in any MEMRI signatures in the 
rTg4510 littermate controls (MAPT, tTA, or wt). These data suggest that rTg4510 mice have 
a much greater rate of manganese uptake and retention in the brain. Interestingly, we 
observed a significant decrease in ΔR1 from 3mo to 10mo of age (Figure 3I). The only 
significant decrease between the different regions over time occurred in CA3.
We then tested the sensitivity of MEMRI to identify alterations in rTg4510 mice prior to the 
onset of cognitive decline. While deficits in synaptic plasticity are detected as early at 3.5 
months in rTg4510 (Abisambra et al., 2013), robust deficits in cognition are readily detected 
in these animals at 4 months of age (Ramsden et al., 2005). We examined mice at 2 and 3 
months of age, prior to the onset of severe cognitive damage. At two months, ΔR1 was 
unchanged between rTg4510 mice and littermate controls (Fig. 4). At three months, rTg4510 
showed significant differences in ΔR1 in the CA1, CA3, dentate gyrus, and cortical brain 
regions compared to 2-month-old rTg4510 mice (Fig. 4). Compared to littermate controls, 
R1 in the CA1 and CA3 region of the hippocampus was significantly increased (Fig. 4). 
Thus, specific tau-related changes in neuronal dysfunction are detectable by MEMRI as 
early as 3 months of age, prior to the onset of severe cognitive impairment in a transgenic 
tau animal model. These data suggest that MEMRI can detect changes in broad neuronal 
function prior to cognitive impairment.
To identify how closely MEMRI deficits are associated with increased pathogenic tau, we 
performed immunohistochemistry on 2- and 3-month-old rTg4510 mice. We first measured 
an early pathological tau conformation detected by the antibody MC1 (Weaver et al., 2000). 
As expected, MC1 immunoreactivity was present in hippocampal sub-regions and the cortex 
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of both 2- and 3-month-old rTg4510 mice (Fig. 5). However, MC1 immunoreactivity was 
significantly increased in the CA3, dentate gyrus, and the superior medial cortex regions of 
these three-month-old tau transgenic mice (Fig. 5).
We next measured the presence of phosphorylated tau species present in pre-tangle 
pathology. Tau is phosphorylated at Ser262 and T231 early during in disease progression in 
AD and other diseases (Goedert et al., 1995; Hirano et al., 1968). Despite the appearance of 
pS262 and pT231 in pre-tangle pathology (Augustinack et al., 2002), we did not detect 
differences in the signal for these phospho-tau species between 2- and 3-month-old rTg4510 
mice (Supplemental Fig. 1). Thus, these data suggest that pre-symptomatic detection of tau-
related changes in neuronal function by MEMRI are associated with the accumulation of the 
earliest conformational markers of pathogenic tau, but not tau hyperphosphorylated at pS262 
or pT231.
4. Discussion
We used MEMRI coupled with high resolution R1 mapping to measure broad neuronal 
function in mice. We identified longitudinal changes in small functional hippo-campal 
regions (Fig. 2), significant neuronal changes in aged tau transgenic mice (Fig. 3), and the 
earliest sign of neuronal dysfunction in tauopathic hippocampus and cortex (Fig. 4). These 
latter changes coincide with appearance of MC1-positive tau but not phospho-tau protein 
aggregates (Fig. 5). An important and critical finding of these studies is the identification of 
the earliest sign of brain alterations in a well-characterized tau mouse model, suggesting that 
MEMRI-R1 can be used to identify the beginning of a viable and potentially more effective 
therapeutic window in brains with neurodegeneration.
This is a highly sensitive approach to perform sub-regional analyses, which permits 
quantification of broad neuronal function in small areas of interest. The derived data offer 
unique insights into tauopathies by establishing areas most susceptible to tau-mediated 
neuronal damage. Future translational efforts could also use MEMRI-R1 to identify subtle 
changes in neuronal function in small regions of the brain in response to interventions.
The molecular mechanisms governing manganese uptake, retention, and clearance in brain 
cells remain incompletely understood. In ten-month-old transgenic mice, we detected 
significantly increased ΔR1 in all the regions analyzed except for the CA3 (Fig. 3). 
Similarly, ΔR1 of three-month-old transgenic mice was significantly increased from age-
matched non-transgenic controls in CA3 and CA1 but not in DG or CTX (Fig. 4). The 
presence of elevated changes in R1 values, correlating with heightened cellular levels of 
manganese, suggests that normal pathways for calcium homeostasis are impacted. Here, it is 
possible that MEMRI-ΔR1 detects calcium dysregulation, which is a major sign of neuronal 
dysfunction that has been previously described (Decker et al., 2015). These data also suggest 
that the mechanisms mediating calcium dysregulation in tauopathy also regulates evident 
manganese mis-sorting. Therefore, manganese is an effective calcium surrogate with 
tremendous potential to reveal changes in calcium dynamics, as an early sign of dysfunction 
in disease. In addition, using manganese to monitor calcium pathways would be a powerful 
means to measure quantitatively the effect of treatments on neuronal function. Data from 
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Figure 3F demonstrates that ΔR1 in CA3 decreases significantly over time. Together with 
the suggestion that CA3 plays an important role in disease progression of rTg4510 mice, our 
data suggest that the CA3 undergoes significant and early changes in rTg4510, which do not 
persist through 10mo compared to controls. Despite lack of persistence, these changes 
suggest that CA3 certainly plays a distinct and crucial role in disease progression worthy of 
further investigation.
Despite the ΔR1 aberrancies in tau transgenic mice, our approach revealed distinct ΔR1 
patterns at three months of age in all imaged brains. In non-transgenic mice, ΔR1 values 
increased at three months (Fig. 2). This pattern was significantly increased in three-month-
old rTg4510 mice compared to two month-old rTg4510, and both two-and three month- old 
littermate controls (Fig. 4). These data highlight important neurological processes at three 
months, which are altered in rTg4510 mice before the appearance of significant tau 
pathology and cognitive impairment.
Our approach builds on previous studies (Antkowiak et al., 2012; Lin and Koretsky, 1997; 
Pautler, 2004; Pautler et al., 1998; Vandsburger et al., 2012) to measure changes in the brain. 
MEMRI offers a powerful approach to quantitatively perform functional and minimally 
invasive measurements in the intact brain. Alternatives that reveal functional measurements, 
particularly in early stages of tauopathy, are terminal procedures such as 
electrophysiological measurements (Abisambra et al., 2013). Other studies employing 
MEMRI to measure changes in rTg4510 mice have also shown important differences. In one 
instance, MEMRI was used to measure transport rates and tract tracing in the olfactory bulb 
and showed that rTg4510 mice present transport deficits along olfactory axons (Majid et al., 
2014). These data in the olfactory tract suggest and support our findings that there are 
neuronal deficits in the hippocampus of tau transgenic mice.
Another study by Perez and colleagues observed neuronal dysfunction in the CA3 of five-
month-old rTg4510 mice using MEMRI (Perez et al., 2013). Since tau pathology ensues 
well before five months in rTg4510 mice, it was reasonable to measure changes at earlier 
time points, which led us to identify MEMRI deficits as early as three months of age in 
rTg4510 mice (Fig. 4). Our approach expands on this finding by adding sensitivity to detect 
abnormal patterns of neuronal dysfunction in the transgenic mice in specific sub-regions 
(DG, CA1, CA3, and CTX) as well as significant differences in both the CA1 and CA3 
when compared to non-transgenic mice. The ability to detect differences in neighboring sub-
regions of the hippocampus suggests that MEMRI is highly sensitive. These data also 
foreshadow a mechanism of disease showing that CA1 and CA3 are the first regions to be 
affected by tau overexpression in the forebrain. Our results are supported by previous 
findings showing that rTg4510 mice present significant tau deposition in CA1 of two-
month-old mice, and that tau aggregation spreads to CA3; tau pathology finally reaches the 
DG by eight months (Ramsden et al., 2005).
Despite the robust differences measured in CA1, DG, and CTX of ten-month-old rTg4510 
mice, we were surprised to find that the CA3 did not show significant differences from 
controls. One possible explanation is that ΔR1 in CA3 is suppressed due to more neuronal 
atrophy in this region compared to other sub-regions of the hippocampus. This would lead to 
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a reduction of voltage gated calcium channels that would impair manganese influx (Pautler, 
2011; Lee and Koretsky, 2005). Interestingly, neuronal dysfunction is detected in rTg4510 
mice at three months in the CA3 and CA1 regions of the hippocampus when compared to 
non-transgenic mice (Fig. 4).
An important consideration in this study is that the rTg4510 model is characterized by 
aggressive pathology (Ramsden et al., 2005; Santacruz et al., 2005). This is in part due to 
increased expression (approximately thirteen times more) of human P301L tau, which is 
associated with onset of fronto-temporal dementia. It would certainly be interesting to 
establish the effect of wild type tau overexpression on ΔR1 changes. Since overexpression of 
wild type tau leads to tauopathic aberrancies (Duff et al., 2000), and many other tauopathies 
are characterized by non-P301L tau tangles, we would expect to determine ΔR1 changes; 
however, the extent of these changes is unknown. On the other hand, the mechanisms of cell 
damage imparted by P301L and wild type pathological tau could be different, and as a result 
ΔR1 might be normal in the latter condition. If this is the case, our approach would be more 
pertinent to FTD, and as such, it would be a unique approach to differentiate FTD from other 
non-P301L tauopathies AD.
Electrophysiological measurements show impaired long-term potentiation deficits as early as 
3–3.5 months in rTg4510 mice suggesting circuitry malfunction in the CA1-CA3 
(Abisambra et al., 2013). Other studies have indicated synaptic density deficits as well as 
spine loss in the rTg4510 mice at 7–9 months without calcium dysregulation (Kopeikina et 
al., 2013; Kuchibhotla et al., 2014). Therefore, compensatory mechanisms could be 
occurring in the circuitry at later time points to adapt to the changes occurring in CA3 at the 
early time point of 3mo where neuronal dysfunction is first detected in the hippocampus 
(Fig. 4). Electrophysiological approaches to measure calcium dysregulation in rTg4510 mice 
at three months of age are currently underway and could highlight a major molecular 
mechanism leading to neuronal dysfunction in early stages of the disease.
5. Conclusions
This study supports the use of MEMRI and R1 mapping as a sensitive and quantitative 
technique to identify changes in broad neuronal function as a consequence of development, 
aging, and disease. Moreover, the MEMRI application described herein has the potential to 
reveal early therapeutic windows for disease and monitor the impact of treatments in 
patients. A major step forward in the field will be translational efforts to use manganese-
based FDA approved compounds in humans such as mangafodipir. Finally, these data 
demonstrate that neurological dysfunction coincides with appearance of MC1 tau and before 
deposition of hyperphosporylated tau pathology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MRI Magnetic resonance imaging
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MEMRI manganese-enhanced MRI
PET positron emission tomography
AD Alzheimer’s disease
PSP progressive supranuclear palsy
FTD fronto-temporal dementia
CA1 cornu ammonis 1
CA3 cornu ammonis 3
DG dentate gyrus
CTX cortex
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Highlights
• We determined age-dependent changes in manganese uptake in a longitudinal 
study of non-transgenic mice, and these signatures were enhanced in sub-
hippocampal regions.
• MEMRI-R1 is a sensitive and quantitative method to detect abnormalities in 
neuronal function as a result of neurodegeneration.
• We established the earliest sign of neuronal dysfunction in tauopathic 
hippocampus and cortex, which correlates with appearance of MC1-positive 
tau but not phospho-tau protein aggregates
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Figure 1. 
Pre and post-manganese parametric ΔR1 maps of a non-transgenic mouse. A) High 
resolution R1 mapping from baseline scans; regions of interest are denoted. B) Same mouse, 
R1 maps from scan taken 6h post-manganese injection.
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Figure 2. 
MEMRI detects age-related changes in manganese uptake in non-transgenic mice. (A–D) 
Representative MEMRI R1 map of littermate control mice at A) 2mo, B) 3mo, C) 6mo, and 
D) 10mo. Quantification of ΔR1 values in E) CA3 F) CA1 G) dentate gyrus (DG) and H) 
superior medial cortex (CTX). (I–J) ΔR1 and one-way ANOVA analysis using Tukey’s 
multiple comparisons test of different brain regions (DG, CA1, CA3, and CTX) in (I) 2mo, 
(J) 3mo, (K) 6mo, and (L) 10mo control mice. All values are mean ± SEM, n= at least 6 per 
group.
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Figure 3. 
Significant MEMRI changes in in aged tauopathic mice. Representative R1 maps of 
MEMRI-scans of 10mo littermate control (A) and 10mo rTg4510 (Tg) mice (B). C) 
Quantification of ΔR1 values in CA3, CA1, dentate gyrus (DG), and superior medial cortex 
(CTX). All values are mean ± SEM, n= 6, *p<0.05.
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Figure 4. 
MEMRI-R1 detects early signs of neuronal dysfunction in transgenic rTg4510 mice prior to 
the onset of cognitive deficits. (A–D) Representative R1 map of A) 2mo littermate control 
B) 3mo littermate control C) 2mo rTg4510 mouse (Tg) and D) 3mo rTg4510 mouse (Tg). 
Quantification of ΔR1 values in E) CA1 F) CA3 G) dentate gyrus (DG), and H) superior 
medial cortex (CTX). (I) ΔR1 comparison between different brain regions (CA3, CA1, DG, 
and CTX) in 3mo and 10mo rTg4510. All values are mean ± SEM, n= at least 4. 
***p<0.001, **p<0.01 *p<0.05.
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Figure 5. 
MEMRI coincides with increased signal of the earliest marker of tau pathology. (A–H) 
Representative immunohistochemistry micrographs (20x objective) from 2- and 3mo 
rTg4510 stained with MC1 tau. (I) Quantification of MC1 levels in CA1, CA3, DG, and 
CTX. Data are mean ± SEM, n=3 mice per group and 2–4 slices per mouse, *p<0.05. (J–L) 
Representative immunohistochemistry micrographs of 3mo rTg4510 mice in the regions 
denoted (CA3, DG, CTX) that were statistically significantly different and show tangle-
bearing neurons and filaments (60x objective).
Fontaine et al. Page 18
Neurobiol Aging. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
